Clinical trial
Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or MET Exon 14 Mutation or ROS1 Translocation (METROS)
NCT02499614 is registered in ClinicalTrials.gov with Fondazione Ricerca Traslazionale as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or MET Exon 14 Mutation or ROS1 Translocation (METROS)
- Lead sponsor
- Fondazione Ricerca Traslazionale
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- December 31, 2014
- Completion date
- December 31, 2018
- Enrollment
- 80 (estimated)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.